Pathophysiological Implications of the Incretin Hormones in Maturity Onset of Diabetes of the Young (MODY)

Plain-language summary

This study investigated the role of incretin hormones in people with maturity onset diabetes of the young (MODY), using glucose tolerance tests, meal tests and treatments such as Sitagliptin. It enrolled adults over 18 who met certain laboratory criteria. It was conducted as a trial with no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

University Hospital, Gentofte, Copenhagen

Intervention

Oral Glucose Tolerance Test (OGTT), iso glycaemic intravenous (iv) glucose infusion (IIGI), Meal test, Sitagliptin, Incretin effect on sulphonyl urea treatment

Start date

1/1/2011

Estimated completion

12/1/2011

Countries

Denmark

Related genes

Locations

• Hellerup, Denmark

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Caucasians above 18 years
* BMI \> 19 kg/m2
* Negative pancreatic beta cell- and glutamate decarboxylase-65(GAD65)- autoantibodies
* Normal haemoglobin
* Normal bloodpressure
* Informed concent

Exclusion Criteria:

* Known liver disease or affected liver enzymes (ALAT/ASAT \>2 x upper normal limit)
* Nephropathy (see creatinine\> 130 μM and / or albuminuria)
* Treatment with medications that cannot be discontinued for 12 hours
* Any condition that the investigators feel would interfere with trial participation
* Pregnancy or lactation